問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Linkou Chang Gung Medical Foundation

  • 0

    Total Beds

  • 0

    Total Doctors

  • 244New Taipei CityLinkou

Recruiting Trial

918Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

2340Cases

2025-02-28 - 2029-08-15

Phase III

Active
A phase 3, randomized, double-blind, placebo-controlled trial of Bleximenib, Venetoclax, and Azacitidine in newly diagnosed acute myeloid leukemia patients with KMT2A gene recombination or NPM1 gene mutation who were ineligible for high-intensity chemotherapy.

  • Condition/Disease

    Acute myeloid leukemia

  • Test Drug

    Azacitidine Bleximenib Venetoclax

Participate Sites
4Sites

Recruiting4Sites

2025-03-01 - 2032-01-31

Phase III

Active
A phase 3, open-label, multicenter, randomized trial comparing trastuzumab deruxtecan plus bevacizumab versus bevacizumab alone as first-line maintenance therapy for HER2-positive ovarian cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112/APGOT-OV13).

  • Condition/Disease

    Compare the efficacy of T-DXd plus bevacizumab (Group A) versus bevacizumab monotherapy (Group B) in the HER2 IHC 3+/2+ population, as assessed by BICR for progression-free survival (PFS).

  • Test Drug

    Trastuzumab Deruxtecan (T-DXd、DS-8201a)

Participate Sites
7Sites

Recruiting7Sites

2025-03-01 - 2030-02-01

Phase III

Active
A multicenter, randomized, open-label, phase III trial (DESTINY-Gastric05) evaluating trastuzumab Deruxtecan (Enhertu®) with chemotherapy (with or without pembrolizumab) versus chemotherapy with or without trastuzumab as first-line treatment for patients with unresectable, locally advanced, or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer.

  • Condition/Disease

    HER2-positive gastric cancer or gastroesophageal junction cancer

  • Test Drug

    Trastuzumab Deruxtecan (T-DXd)

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2034-05-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

  • Condition/Disease

    Cervical Cancer

  • Test Drug

    注射劑 注射劑 注射劑

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2029-03-27

Others

Not yet recruiting
A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease

  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    注射劑

Participate Sites
3Sites

Recruiting3Sites

2025-11-01 - 2027-08-22

Phase II

Active
A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease

  • Condition/Disease

    Drug-Related Side Effects and Adverse Reactions

  • Test Drug

    皮下注射劑

Participate Sites
5Sites

Recruiting5Sites

2025-11-01 - 2030-12-31

Phase III

Active
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants

  • Condition/Disease

    Focal Segmental Glomerulosclerosis

  • Test Drug

    膜衣錠 膜衣錠

Participate Sites
9Sites

Recruiting9Sites

2025-11-01 - 2030-05-18

Phase III

Active
A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

  • Condition/Disease

    Epithelial Ovarian Cancer

  • Test Drug

    注射用凍晶粉末 靜脈輸注液 輸注液 輸注液 濃縮粉劑 輸注液

Participate Sites
9Sites

Recruiting9Sites

2025-11-01 - 2031-12-31

Phase III

Active
A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

  • Condition/Disease

    Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    凍晶乾燥注射劑 注射劑

Participate Sites
8Sites

Not yet recruiting1Sites

2025-11-01 - 2030-12-31

Phase III

Active
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

  • Condition/Disease

    Prostatic Neoplasms, Castration-Resistant

  • Test Drug

    靜脈輸注液 靜脈輸注液 錠劑

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5 6 234
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB